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Background. The aim of this study was to understand the factors influencing the use of 
surgical options by New Zealand women with newly diagnosed breast cancer. Method. 
Using data from the Auckland and Waikato breast cancer registers, we included 11798 
women diagnosed with stage I-III breast cancer from June 2000-May 2013. The 
characteristics of women receiving different surgical treatments and having immediate breast 
reconstruction following mastectomy were examined. A logistic regression was used to 
estimate the odds ratio of having breast-conserving surgery (BCS) versus mastectomy and 
immediate post mastectomy reconstruction. Bilateral breast cancer cases and women with 
unilateral breast cancer, but who had bilateral surgery, were also identified. Results. Fifty-
two percent of women received BCS and 44% had mastectomy over the study period. Key 
influences associated with BCS were age, mode of diagnosis, socio-economic status and 
public or private treatment. Just under half of women who underwent bilateral surgery did not 
have bilateral cancer. Nineteen percent of women undergoing mastectomy underwent 
immediate reconstruction. Implant use increased slightly over the study period but there was 
a decrease in the use of autologous flap procedures. Conclusion. Surgical management of 
women with localised breast cancer was generally in line with guidelines, but with potential 
to further increase use of breast conservation and immediate reconstruction in suitable 
cases.  
 








New Zealand (NZ) has a population of 4.5 million, of which 1.9 million live in and about the 
Auckland and Waikato regions. Three thousand NZ women are diagnosed with breast 
cancer each year. The primary treatment for 95% of women with localised breast cancer is 
surgery. Historically, surgical treatment has involved mastectomy1, but in 1990 the National 
Institutes of Health Consensus Conference recommended breast conserving surgery (BCS) 
followed by radiotherapy (RT) as the treatment of choice for early stage breast cancer in 
suitable cases2. These recommendations led to a steady increase in the uptake of BCS3. 
More recently, however, rates of mastectomy have been seen to increase in the U.S.4, even 
in women with breast cancer that is suitable for BCS5.  
Reasons why women choose BCS or mastectomy are multi-factorial. Factors 
influencing decision-making include surgeon opinion6, tumour size (and size relative to 
breast size) and location7, access to  RT8, socioeconomic status and education level9, 
ethnicity10, co-morbidity11, use of pre-operative MRI4, BRCA status8 and family history6. Fear 
of recurrent cancer is an important factor driving the uptake of mastectomy, which offers a 
perception of reduced risk and avoidance of repeat treatments or RT associated with BCS6. 
In contrast, BCS is perceived as less radical, with a positive cosmetic outcome and body 
image2, 6. From a surgical perspective, more women are becoming suitable for BCS with 
growing training and use of oncoplastic techniques, including reduction or volume 
replacement techniques. 
A small number of women are diagnosed with cancer in both breasts and undergo 
bilateral surgery – usually bilateral mastectomy. In some cases, women with uni-lateral 
disease choose bilateral mastectomy to prevent cancer in the other breast5, despite no 
clinical evidence to support any further survival benefit12. In addition, an increasing option for 
women choosing mastectomy is to have immediate breast reconstruction13, using either 
autologous techniques (deep inferior epigastric perforator artery (DIEP) flaps, transverse 
rectus abdominis myocutaneous (TRAM) flaps and latissimus dorsi (LD) flaps) or implant 
based reconstruction14.  
This study examines the different surgical options used in a large cohort of NZ 
women with newly diagnosed breast cancer, and the sociodemographic and ethnic factors 








This study is based on data from two cancer registers (Auckland and Waikato), which 
have prospectively collected data from almost 100% of newly diagnosed breast cancer 
cases. Data are entered on to the registers through clinic and operation records, multi-
disciplinary meeting records, oncology, palliative care and private and public hospital 
records15. We included 11798 women diagnosed with stage I-III breast cancer between June 
2000 and May 2013, and excluded 574 women with metastatic disease and men with a 
breast cancer diagnosis. Patient consent to access data from both registers was not required 
(ethics ref: WAI/04/10/099/AM02). 
Information in the combined registers includes (but is not limited to): 1) patient 
characteristics: age, diagnosis date, mode of diagnosis, socio-economic status, 
public/private, region (Auckland/Waikato) and ethnicity; 2) tumour biology: cancer stage, 
grade, and tumour size; 3) treatment: chemotherapy, surgery and radiotherapy; and 4) 
cancer progression: local recurrence, metastases and date of death. The presence of co-
morbidities was ascertained by data linkage to the National Minimum Dataset (NMDS) that 
records clinical data for inpatients and day patients. We characterised patients as having no 
co-morbidities (C0), one co-morbidity (C1) or 2 or more (C2+) using the C3 co-morbidity 
count16. 
Surgical choices were categorised as either BCS, mastectomy or no primary surgery. 
We recorded surgery to one or both breasts, and whether women choosing mastectomy 
opted for breast reconstruction. Reconstructive surgery was categorised as DIEP/TRAM 
flaps, LD flaps or implants/expanders. We identified bilateral breast cancer cases and 
women who had unilateral breast cancer but had bilateral surgeries. 
Descriptive statistics for categorical variables are displayed as actual 
numbers/percentages and compared between groups using Chi square tests. All tests of 
significance were two tailed, with P<0.05 considered significant. Sociodemographic and 
disease factors associated with the receipt of BCS (versus mastectomy), as well as the 
receipt of post-mastectomy breast reconstruction were determined using logistic regression 
to obtain odds ratios (OR’s). All statistical analyses were performed in SPSS version 23 
(New York, United States). 
Ethical approval for the study was granted through the Northern A Health and 










Of the 11798 women diagnosed with stage I-III breast cancer between June 2000 
and May 2013, 6149 (52%) women had BCS, 5179 (44%) had mastectomy, and 470 (4%) 
had no primary surgery (Table 1). The probability of having BCS compared to mastectomy 
was greatest in the screening age range, and decreased with age (Table 2).  Women living 
in the Waikato (OR: 1.60, 95% CI 1.44-1.78) and those with screened detected cancers (OR: 
2.23, 95% CI: 2.04-2.43) were more likely to have BCS. Women treated in a public hospital 
(OR: 0.70, 95% CI: 0.64-0.77), living in the most deprived socioeconomic quintile (9-10) (OR: 
0.76, 95% CI: 0.66-0.87) and with higher cancer stage (OR 0.36 (95% CI: 0.33-0.39) for 
stage II vs stage I; OR 0.13 (95% CI: 0.11-0.15) for stage III vs stage I) were less likely to 
receive BCS.  
 
Breast reconstruction after mastectomy 
After mastectomy, 972 (19%) women had immediate breast reconstruction: 434 (45%) 
DIEP or TRAM flaps, 131 (13%) LD flaps, and 407 (42%) implant/expander reconstruction 
(Table 3). The rate of immediate reconstruction increased from 17% in 2000-2003 to 21% in 
2010-2013. Implant/expander reconstruction increased from 12% in 2000-2003 to 56% in 
2010-2013, and the use of DIEP and TRAM flaps decreased from 68% in 2000-2003 to 31% 
in 2010-2013.  
Logistic regression showed that ethnicity, public/private hospital, having post-
mastectomy RT, region, cancer stage, co-morbidity, screen detection, age and year of 
diagnosis had a significant impact on the likelihood of having breast reconstruction following 
mastectomy (Table 4). The adjusted OR’s of having breast reconstruction were 0.53 (95% CI: 
0.38-0.73) and 0.46 (95% CI: 0.31-0.67) for Māori and Pacific women compared to others; 
0.43 (95% CI: 0.36-0.51) for women treated publically compared to privately; 0.59 for (95% 
CI: 0.45-0.78) for women living in the most deprived socioeconomic quintile (9-10); 0.76 (95% 
CI: 0.62-0.92) for those who had RT compared to those who did not; 1.41 (95% CI: 1.14-
1.75) for Waikato patients compared to Auckland patients; 0.78 (95% CI: 0.64-0.95) and 
0.52 (95% CI: 0.40-0.68) for women with stage II and III cancer compared to women with 
stage I cancer; 0.36 (95% CI: 0.23-0.57) for women with co-morbidity of 2+ compared to no 
co-morbidity, and 1.87 (95% CI: 1.55-2.26) for women who were screen detected compared 
to those who were not; 0.91 (95% CI: 0.90-0.92) for age; and 1.03 (95% CI: 1.01-1.05) for 
year of diagnosis. An additional 142 women had delayed reconstruction, although this may 






Bilateral cancer and bilateral surgeries 
We found 295 (3%) women diagnosed with bilateral breast cancer, including 236 
from Auckland and 59 from Waikato. Of these, 174 (59%) women had bilateral mastectomy, 
82 (28%) had bilateral BCS, 17 (6%) had BCS and mastectomy on each side, and 22 (8%) 
had no primary surgery. After bilateral mastectomy, 51 (29%) had immediate bilateral breast 
reconstruction. 
There were 290 (2%) women diagnosed with unilateral breast cancer, but who 
underwent bilateral surgery, including 242 from Auckland and 48 from the Waikato. Of these, 
285 (98%) women had a bilateral mastectomy. Following bilateral mastectomy, 79 (28%) 
had immediate bilateral breast reconstruction. The rates of bilateral mastectomy in women 









Mastectomy is still used in women with primary breast cancer that is potentially suitable for 
BCS. In this NZ cohort, we found slightly more use of BCS, with 52% of women receiving 
BCS while 44% of women received a mastectomy. More use of BCS is in contrast to reports 
of a steady rise in the use of mastectomy in the U.S.3, 4 but is in accordance with Australian 
BCS rates of 61% over similar time periods17. Women diagnosed through screening, even 
after adjustment for age and stage, were twice as likely to receive BCS, while only 29% 
underwent a mastectomy. In 2004, the eligible age range for screening in NZ was widened 
to include women 45-49 years in addition to the 50-69 year age group, which could partly 
explain the slightly higher rate of BCS. We have shown fairly stable rates of mastectomy, 
slightly higher than the reported rate of 39% in Australia over a similar time period17, higher 
than U.K. audit data for screen detected cancers of 23% from 2013/14-2014/15 18, and within 
variable provincial Canadian rates of 26%-69%19.  
It has been reported elsewhere that younger women, particularly <40 years of age, 
are more likely to choose mastectomy3, 4, 5. We report similar data, with 61% of women aged 
<40 opting for mastectomy. Younger women have a higher likelihood of being BRCA gene 
mutation positive4, 5 and have a higher risk of local recurrence after BCS. Fear of recurrence 
has a major influence on decision-making for this age group. Women older than the NZ 
screening range (45-69) were also more likely to choose mastectomy.  
Women living in the Waikato region were more likely to be treated with BCS, even 
after adjustment for stage, grade and size of tumour. Surgeon or system differences could 
account for some of the variation in the type of surgery chosen. The level of surgeon 
influence on women’s surgery decisions is a significant factor in published studies3, 6, 10, 20. 
Patients treated publicly and those living in the most deprived socioeconomic quintile (9-10) 
were less likely to receive BCS. Social deprivation likely plays a role in decision-making8, 9 
and lower rates of breast reconstruction21 and may also indirectly relate to differences in 
surgical treatment between the public and private sector10.    
Only 586 women underwent bilateral surgery, and 290 (50%) of these did not have 
bilateral cancer. Bilateral mastectomy reduces the risk of contralateral breast cancer 
following unilateral disease, but does not increase survival in BRCA1/2 mutation negative 
women12. Reasons why women choose bilateral surgery are related to clinical, psychological 
and cosmetic outcomes12, anxiety surrounding future treatments, family history9, and being 
BRCA or other gene mutation positive22. Fear of recurrence and a misperception of 
enhanced survival are major influences12, with younger women more anxious than older 
women23 and therefore more likely to opt for bilateral mastectomy9, 22, 23.  In the current 





<60 years of age, and as age increased, the likelihood of having a bilateral mastectomy 
decreased.   
The uptake of breast reconstruction has been increasing slowly over time13. In this 
cohort, immediate reconstruction increased from 17-21% at the end of the study period. This 
compares to a rate of 12-16% in Australia24, an average regional rate of 21% in the UK25 and 
26% in the U.S.26. In our study, the crude percentages of reconstruction between the two NZ 
regions were similar, but the OR for breast reconstruction in the Waikato was 40% higher 
than in Auckland after adjusting for greater deprivation and use of post mastectomy 
radiotherapy in the Waikato. Regional differences can be due to a mixture of patient factors 
(age, social deprivation), system factors (size and location of treatment facilities) and 
surgeon preferences (e.g., timing and suitability for reconstruction, and preferred method 
such as implants alone vs. use of LD flaps). Regional differences have also been reported in 
the U.S., where up to 84% of caucasian women in areas with a high density of plastic 
surgeons, and private insurance, undergo immediate reconstruction27. 
Women identified through breast screening but who chose mastectomy were also 
more likely to have reconstruction. There are many possible reasons for this, including, 
higher health literacy, fewer Māori and Pacific women in this population, and a higher 
proportion of screened women having tumours that do not require RT, e.g., extensive DCIS. 
Compared with NZ European, Māori and Pasifika women were significantly less likely to 
undergo breast reconstruction. Ethnic disparities have been reported previously10 and may in 
part be influenced by factors such as smoking and obesity. Other factors influencing whether 
women receive reconstruction (but not addressed in this study) include living remotely28, 
surgeon caseloads or large tumour size24.  
There was a decrease in the use of autologous procedures (DIEP, TRAM and LD 
flaps) and an increase in the use of implants from 12% in 2000-03 to 56% in 2010-13 (Table 
3). This trend has also been reported elsewhere 29 and is likely due to improvements in 
implant techniques, with growing use of acellular dermal matrices and subsequent use of fat 
grafting, whilst avoiding the morbidity associated with autologous methods. Autologous 
procedures also often involve specialist plastic surgical input, which additionally makes the 
scheduling and timely provision of surgery more difficult.  
The relatively large sample is a strength of this study. The sample was derived from 
generally complete population based datasets. A limitation is that we restricted our analysis 
on breast reconstruction to immediate surgeries, as we were concerned that there may be 
an under-recording of delayed surgical intervention. However, we believe the proportion of 
delayed breast reconstruction is less than 10% of the total.  
This study examines the different surgical options used in a large cohort of NZ 





the study period, perhaps explained by the increase in diagnoses through screening. 
Mastectomy was more likely in older women, but more women in the <40 age group were 
also opting for mastectomy, which is in accordance with trends reported elsewhere. Almost 3% 
of women underwent bilateral mastectomy despite having unilateral breast cancer. We 
report growing rates of immediate breast reconstruction, with an increase in implant based 
reconstruction techniques. By international standards, there is room for improvement in both 
breast conservation rates, and use of immediate breast reconstruction. 
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Table 1. Characteristics of women receiving different surgical treatments. 
Factors No primary surgery BCS Mastectomy Total 
 P-value  
(Chi-square test) 
 N % N % N % N  
Register        <0.001 Auckland 354 3.8% 4689 50.9% 4175 45.3% 9218  Waikato 116 4.5% 1460 56.6% 1004 38.9% 2580  
         Year of diagnosis        0.105 2000-03 133 4.7% 1461 51.1% 1266 44.3% 2860  2004-06 85 3.3% 1323 51.9% 1140 44.7% 2548  2007-09 112 3.9% 1477 51.6% 1276 44.5% 2865  2010-13 140 4.0% 1888 53.6% 1497 42.5% 3525  
         Ethnicity        <0.001 Māori 39 3.6% 517 48.2% 516 48.1% 1072  Pacific 58 8.0% 273 37.9% 390 54.1% 721  Non- Māori/non-Pacific 373 3.7% 5359 53.6% 4273 42.7% 10005  
         Age        <0.001 <40 9 1.2% 283 37.5% 463 61.3% 755  40-49 31 1.2% 1327 51.5% 1219 47.3% 2577  50-59 39 1.2% 1929 59.8% 1258 39.0% 3226  60-69 37 1.3% 1743 63.3% 975 35.4% 2755  70-79 67 4.6% 623 42.8% 764 52.5% 1454  80+ 287 27.8% 244 23.7% 500 48.5% 1031  
         Mode of detection        <0.001 Not screen detected 431 6.1% 2827 39.8% 3837 54.1% 7095  Screen detected 39 0.8% 3322 70.6% 1342 28.5% 4703  
         Stage        <0.001 Stage I 99 1.8% 3854 71.9% 1404 26.2% 5357  Stage II 264 5.8% 1921 42.0% 2385 52.2% 4570  Stage III 107 5.7% 374 20.0% 1390 74.3% 1871  
         Public/Private        <0.001 Private 36 0.8% 2751 60.2% 1785 39.0% 4572  Public 434 6.0% 3398 47.0% 3394 47.0% 7226           
Deprivation        <0.001 
1 to 2 (low deprivation) 73 2.9% 1402 55.7% 1044 41.4% 2519  
3 to 4 77 3.9% 1070 54.7% 809 41.4% 1956  
5 to 6 89 3.5% 1358 53.9% 1074 42.6% 2521  
7 to 8 105 4.5% 1211 51.4% 1042 44.2% 2358  
9 to 10 (high deprivation) 115 4.9% 1055 45.2% 1164 49.9% 2334  
Unknown 11 10.0% 53 48.2% 46 41.8% 110  
         Co-morbidity count        <0.001 0 176 1.9% 5067 54.6% 4036 43.5% 9279  1 44 4.7% 453 48.6% 436 46.7% 933  2+ 250 15.8% 629 39.7% 707 44.6% 1586  









Factors P-value OR (95% CI) 
Co-morbidity count   
1 vs 0 0.106 0.88 (0.75-1.03) 
2+ vs 0 0.086 0.89 (0.78-1.02) 
   
Year of diagnosis 0.360 1.00 (0.98-1.01) 
   
Register: Waikato vs Auckland <0.001 1.60 (1.44-1.78) 
   
Age <0.001 0.99 (0.99-1.00) 
   
Ethnicity   
Māori vs Non- Māori/non-Pacific 0.971 1.00 (0.86-1.17) 
Pacific vs Non- Māori/non-Pacific 0.521 0.94 (0.78-1.13) 
   
Public vs Private <0.001 0.70 (0.64-0.77) 
   
Deprivation   
3-4 vs 1-2 0.978 1.00 (0.87-1.14) 
5-6 vs 1-2 0.635 0.97 (0.85-1.10) 
7-8 vs 1-2 0.382 0.94 (0.82-1.08) 
9-10 vs 1-2 <0.001 0.76 (0.66-0.87) 
   Stage   
Stage II vs Stage I <0.001 0.36 (0.33-0.39) 
Stage III vs Stage I <0.001 0.13 (0.11-0.15) 
   
Screen Detected vs Not screen 
detected 





Table 3. Characteristics of women having immediate breast reconstruction following mastectomy. 










test)  N % N % N % N % 
Register         <0.001 Auckland 789 18.9% 363 46.0% 47 6.0% 379 48.0%  Waikato 183 18.2% 71 38.8% 84 45.9% 28 15.3%  
          Year of diagnosis   <0.001 2000-03 217 17.1% 147 67.7% 43 19.8% 27 12.4%  2004-06 195 17.1% 92 47.2% 29 14.9% 74 37.9%  2007-09 250 19.6% 98 39.2% 19 7.6% 133 53.2%  2010-13 310 20.7% 97 31.3% 40 12.9% 173 55.8%  
          Ethnicity         <0.001 Māori 54 10.5% 27 50.0% 9 16.7% 18 33.3%  Pacific 37 9.5% 16 43.2% 1 2.7% 20 54.1%  Others 881 20.6% 391 44.4% 121 13.7% 369 41.9%  
          Age         <0.001 <40 180 38.9% 71 39.4% 25 13.9% 84 46.7%  40-49 389 31.9% 174 44.7% 46 11.8% 169 43.4%  50-59 313 24.9% 157 50.2% 48 15.3% 108 34.5%  60-69 84 8.6% 31 36.9% 11 13.1% 42 50.0%  70-79 5 0.7% 1 20.0% 1 20.0% 3 60.0%  80+ 1 0.2%     1   
          Mode of detection      Not screen 
detected 639 16.7% 294 46.0% 88 13.8% 257 40.2% <0.001 
Screen detected 333 24.8% 140 42.0% 43 12.9% 150 45.0%  
          Stage         <0.001 Stage I 344 24.5% 134 39.0% 50 14.5% 160 46.5%  Stage II 435 18.2% 200 46.0% 56 12.9% 179 41.1%  Stage III 193 13.9% 100 51.8% 25 13.0% 68 35.2%  
          Public/Private        <0.001 Private 558 31.3% 301 53.9% 61 10.9% 196 35.1%  Public 414 12.2% 133 32.1% 70 16.9% 211 51.0%            
Deprivation        <0.001 
1 to 2 265 25.4% 135 50.9% 22 8.3% 108 40.8%  
3 to 4 188 23.2% 76 40.4% 14 7.4% 98 52.1%  
5 to 6 199 18.5% 81 40.7% 34 17.1% 84 42.2%  
7 to 8 173 16.6% 81 46.8% 30 17.3% 62 35.8%  
9 to 10 133 11.4% 52 39.1% 30 22.6% 51 38.3%  
Unknown 14 30.4% 9 64.3% 1 7.1% 4 28.6%  
          Comorbidity 
count         <0.001 





Table 4. Odds ratio of having immediate reconstruction or not after mastectomy. 
 
Factors P-value OR (95% CI) 
Ethnicity   
Māori vs Non- Māori/non-
Pacific 
<0.001 0.53 (0.38-0.73) 
Pacific vs Non- Māori/non-
Pacific 
<0.001 0.46 (0.31-0.67) 
   
Public vs Private <0.001 0.43 (0.36-0.51) 
   
Deprivation   
3-4 vs 1-2 0.355 0.89 (0.70-1.14) 
5-6 vs 1-2 0.116 0.82 (0.65-1.05) 
7-8 vs 1-2 0.226 0.85 (0.66-1.10) 
9-10 vs 1-2 <0.001 0.59 (0.45-0.78) 
   
Radiotherapy vs no 
radiotherapy 
0.006 0.76 (0.62-0.92) 
   
Register: Waikato vs 
Auckland 
0.002 1.41 (1.14-1.75) 
   
Stage   
Stage II vs Stage I 0.012 0.78 (0.64-0.95) 
Stage III vs Stage I <0.001 0.52 (0.40-0.68) 
   
   
Co-morbidity count   
1 vs 0 0.069 0.73 (0.51-1.03) 
2+ vs 0 <0.001 0.36 (0.23-0.57) 
   
Screen Detected vs Not 
screen detected 




Age <0.001 0.91 (0.90-0.92) 
   
Year of diagnosis 0.012 1.03 (1.01-1.05) 
 
 
